Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
Lobe Sciences and its subsidiary Alera Pharma have received a second patent allowance for Conjugated Psilocin™ from the U.S. Patent Office. The patent covers compositions comprising psilocin mucate salt or conjugate and their production methods. Conjugated Psilocin™ is a stable, highly bioavailable analogue of psilocin, the active metabolite of psilocybin, with potential applications in treating neurological disorders, particularly chronic cluster headache. The intellectual property rights will be assigned to Alera Pharma, which is currently pursuing fundraising activities for drug development.
Lobe Sciences e la sua sussidiaria Alera Pharma hanno ricevuto un secondo riconoscimento di brevetto per Conjugated Psilocin™ dall'Ufficio Brevetti degli Stati Uniti. Il brevetto copre le composizioni che comprendono il sale mucato di psilocina o il coniugato e i loro metodi di produzione. Conjugated Psilocin™ è un analogo stabile e altamente biodisponibile della psilocina, il metabolita attivo della psilocibina, con potenziali applicazioni nel trattamento dei disturbi neurologici, in particolare l'emicrania a grappolo cronica. I diritti di proprietà intellettuale saranno trasferiti ad Alera Pharma, che attualmente sta perseguendo attività di raccolta fondi per lo sviluppo di farmaci.
Lobe Sciences y su filial Alera Pharma han recibido una segunda concesión de patente para Conjugated Psilocin™ de la Oficina de Patentes de EE. UU. La patente cubre composiciones que comprenden la sal mucato de psilocina o el conjugado y sus métodos de producción. Conjugated Psilocin™ es un análogo estable y altamente biodisponible de la psilocina, el metabolito activo de la psilocibina, con aplicaciones potenciales en el tratamiento de trastornos neurológicos, particularmente la cefalea en racimo crónica. Los derechos de propiedad intelectual serán asignados a Alera Pharma, que actualmente está llevando a cabo actividades de recaudación de fondos para el desarrollo de fármacos.
Lobe Sciences와 그 자회사 Alera Pharma가 미국 특허청으로부터 Conjugated Psilocin™의 두 번째 특허 허가를 받았습니다. 이 특허는 psilocin mucate salt 또는 그 콘쥬게이트를 포함하는 조성과 그 제조 방법을 포함합니다. Conjugated Psilocin™은 psilocybin의 활성 대사물인 psilocin의 안정적이고 생체 이용률이 높은 유사체로, 신경계 질환, 특히 만성 군발 두통 치료에 잠재적인 응용이 있습니다. 지적 재산권은 현재 약물 개발을 위한 자금 조달 활동을 진행 중인 Alera Pharma에 양도될 것입니다.
Lobe Sciences et sa filiale Alera Pharma ont reçu une deuxième autorisation de brevet pour Conjugated Psilocin™ de l'Office des brevets des États-Unis. Le brevet couvre des compositions comprenant du sel de mucate de psilocine ou un conjugé ainsi que leurs méthodes de production. Conjugated Psilocin™ est un analogue stable et hautement biodisponible de la psilocine, le métabolite actif de la psilocybine, avec des applications potentielles dans le traitement des troubles neurologiques, en particulier la céphalée en grappes chronique. Les droits de propriété intellectuelle seront transférés à Alera Pharma, qui poursuit actuellement des activités de levée de fonds pour le développement de médicaments.
Lobe Sciences und seine Tochtergesellschaft Alera Pharma haben vom U.S. Patentamt eine zweite Patentgenehmigung für Conjugated Psilocin™ erhalten. Das Patent umfasst Zusammensetzungen, die Psilocin-Mucatsalz oder Konjugate enthalten, sowie deren Herstellungsverfahren. Conjugated Psilocin™ ist ein stabiles, hoch bioverfügbares Analogon von Psilocin, dem aktiven Metaboliten von Psilocybin, mit potenziellen Anwendungen bei der Behandlung neurologischer Störungen, insbesondere der chronischen Clusterkopfschmerzen. Die geistigen Eigentumsrechte werden an Alera Pharma übertragen, das derzeit Aktivitäten zur Mittelbeschaffung für die Arzneimittelentwicklung durchführt.
- Received second U.S. patent allowance for Conjugated Psilocin™
- Product shows superior pharmacokinetics including rapid and reproducible absorption
- Demonstrates improved stability and bioavailability compared to traditional psilocin
- Still requires fundraising to proceed with drug development
- Product is in early development stage without proven clinical efficacy
-
U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™ - Once issued, this patent will provide additional coverage for psilocin mucate compositions
Lobe Sciences will assign the intellectual property rights associated with this patent to Alera Pharma, its wholly owned subsidiary. Mr. Rick Goulburn, CEO of Alera Pharma, Inc. stated, “we are excited to receive this allowance for a second patent on Conjugated Psilocin™ which recognizes the unique properties of this psilocin analogue invention. We are proceeding with our fund-raising activities to develop Conjugated Psilocin™ for the treatment of Chronic Cluster Headache.”
Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences also commented, “As we continue to gather more data on Conjugated Psilocin™, we realize that this new chemical entity may enable us to develop a wide range of applications.” He continued, “Conjugated Psilocin™ is a stable form of psilocin, the active metabolite of psilocybin with attractive pharmacokinetics including rapid and reproducible absorption. Both these attributes may make this active ingredient superior to psilocybin itself.”
About Conjugated Psilocin™
Conjugated Psilocin™ is a patented, novel, oral, stable analogue of psilocin, the active metabolite of the prodrug psilocybin. Psilocybin is a psychedelic compound that has been identified as having therapeutic potential in a variety of neurological conditions. Psilocybin is dephosphorylated to the active moiety psilocin with poor bioavailability and pharmacokinetics. Psilocin itself is a very unstable compound that has been difficult to develop as a pharmaceutical medicine. Conjugated Psilocin™ is a stable, highly bioavailable pharmaceutical ingredient with the potential to be developed as a prescription medicine in a variety of neurological disorders.
About Lobe Sciences Ltd.
Lobe Sciences, Ltd. is a commercial stage biotechnology company focused on developing transformative therapies for unmet medical needs. Through its subsidiaries, Alera Pharma, Inc. and Altemia, Inc., Lobe Sciences is developing patented drug candidates to treat chronic cluster headache (Alera) and innovative medical foods to address deficiencies commonly seen in sickle cell disease (Altemia). Lobe Sciences provides common services to its subsidiaries including accounting, finance, and general administrative services.
About Alera Pharma, Inc.
Alera Pharma, Inc. is a wholly owned and private subsidiary of Lobe Sciences, Ltd., dedicated to the development and commercialization of innovative pharmaceutical products. With a focus on addressing unmet medical needs, Alera Pharma is committed to improving patient outcomes in a variety of neurological disorders through cutting-edge research and development.
Cautionary Statement Regarding "Forward-Looking" Information
This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the additional coverage provided by the new patent; the anticipated assignment of the intellectual property rights associated with the new patent; the expected fund-raising activities of the Company; and the Company’s beliefs regarding potential applications of Conjugated Psilocin™, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur.
Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: once issued, the new patent will provide additional coverage for psilocin mucate compositions; that Lobe Sciences will assign the intellectual property rights associated with the new patent to Alera Pharma; that the Company will proceed with its expected fund-raising activities, and that the proceeds therefrom will be used to develop Conjugated Psilocin™ for the treatment of Chronic Cluster Headache; and that Conjugated Psilocin™ may enable the Company to develop a wide range of applications. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the Company will not receive a second patent for Conjugated Psilocin™; that the new patent will not provide additional coverage for psilocin mucate compositions; that Lobe Sciences will not assign the intellectual property rights associated with the new patent to Alera Pharma, or at all; that the Company will not proceed with its fund-raising activities, or that the proceeds from the Company’s fund-raising activities will not be used to develop Conjugated Psilocin™ for treatment of Chronic Cluster Headaches; and that Conjugated Psilocin™ may not enable the Company to develop a wide range of applications.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241119109797/en/
Dr. Fred D. Sancilio, CEO
Lobe Sciences Ltd.
Investor and Media
Info@Lobesciences.com
www.lobesciences.com
Source: Lobe Sciences Ltd.
FAQ
What is the latest patent approval for Lobe Sciences (LOBEF)?
What are the advantages of Lobe Sciences' (LOBEF) Conjugated Psilocin™?
What medical condition is Lobe Sciences (LOBEF) targeting with Conjugated Psilocin™?
